The Endeavor CEO was enlisted to join investors who put in an unsolicited offer to buy OpenAI's majority share of its for-profit arm.
Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback